Bangladesh vs Uruguay: HIV/AIDS deaths averted by antiretroviral therapy
Bangladesh
479.38 deaths
in 2024
Uruguay
516 deaths
in 2022
Bangladesh rank
94th
Uruguay rank
91st
HIV/AIDS deaths averted by antiretroviral therapy over time
- Bangladesh
- Uruguay
How they compare
Uruguay currently reports 516 deaths against 479.38 deaths in Bangladesh, a difference of 36.62 deaths.
That makes Uruguay's figure about 1.1 times Bangladesh's.
Across all 33 years both countries report, Uruguay has been ahead every year.
Bangladesh ranks 94th and Uruguay ranks 91st of 157 countries.
Uruguay has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Bangladesh | Uruguay | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 25 deaths | 25 deaths | Uruguay |
| 2000s | 13.01 deaths | 166.5 deaths | 153.49 deaths | Uruguay |
| 2010s | 178.72 deaths | 364 deaths | 185.28 deaths | Uruguay |
| 2020s | 347.67 deaths | 487 deaths | 139.33 deaths | Uruguay |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Bangladesh or Uruguay?
- Uruguay, at 516 deaths against 479.38 deaths in Bangladesh as of 2022.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Bangladesh and Uruguay?
- 36.62 deaths, with Uruguay ahead.
- How many years of comparable data are there for Bangladesh and Uruguay?
- 33 years are reported by both, from 1990 to 2022.
- How do Bangladesh and Uruguay rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Bangladesh ranks 94th and Uruguay ranks 91st of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.